About
Our journey
Our journey
Abcam was established in 1998 by Jonathan Milner, David Cleevely and Tony Kouzarides in Cambridge, UK. Their mission was to source and sell online the best research antibodies in the world, together with the most comprehensive data, fast delivery, helpful customer service and technical support.
Today, with over 20 years of experiences, facilities in Europe, USA and Asia and customers in over 130 countries, we are a leading global proteomics pioneer that identifies, develops, and manufactures quality biological, protein, and custom cell engineering tools to the life science research and clinical communities.
Abcam established and in the first twelve months focuses on setting up a web-based offering to sell the best antibodies in the world with the most comprehensive data, fast delivery and helpful customer service and technical support
Founders: Dr Jonathan Milner, David Cleevely, Prof Tony Kouzarides
First overseas office opened in Cambridge, MA
Abcam plc floated on the AIM market of the London Stock Exchange
Sales of £12.1 million (2004/5)
Mitosciences acquired, bringing immunoassay capabilities in-house
Ascent Scientific Ltd acquired, enhancing Abcam’s offering in high-performance biochemicals
Chinese office in Shanghai opened
Annual revenue surpasses £100m for the first time (£122.2m for FY2012/13)
Alan Hirzel appointed as CEO
Long-term invest-to-grow strategy initiated
Firefly BioWorks acquired, adding multiplex and MiRNA assay capabilities
AxioMx acquired, proving in vitro recombinant monoclonal antibody capabilities (phage display)
Annual revenue surpasses £200m for the first time (£217.1m for FY2016/17)
Agreement signed with Roche covering Spring Bioscience portfolio of over 750 products
Number of recombinant RabMAb antibodies available surpasses 13,000
Calico Biolabs acquired (custom rabbit monoclonal antibody) capabilities
EdiGene acquired (cell line and lysate portfolio
Cancer Research UK – custom partnership to accelerate cancer research
Marker Gene Technologies acquired (biology and organic chemistry)
Applied StemCell acquired (cell engineering and gene editing)
Expedeon acquired proteomics and immunology (conjugation)
(£217.1m for FY2016/17)
Adding multiplex and MiRNA assay capabilities
Proving in vitro recombinant monoclonal antibody capabilities (phage display)
(£122.2m for FY2012/13)
Enhancing Abcam’s offering in high-performance biochemicals
Bringing immunoassay capabilities in-house
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy policy